REGENERON PHARMACEUTICALS, INC. Financing Cash Flow
REGENERON PHARMACEUTICALS, INC. (REGN) reported Financing Cash Flow of -$2.03 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$1.22B.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$802.20M.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$780.10M.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$717.90M.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was -$3.72B.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$2.20B.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$1.79B.
- REGENERON PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$1.01B.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.03B 10-Q · filed 2026-07-30 | -$2.81B derived: sum of 3 quarters · filed 2026-07-30 | -$3.52B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | -$802.20M 10-Q · filed 2026-04-29 | -$1.58B derived: sum of 2 quarters · filed 2026-04-29 | -$2.30B derived: sum of 3 quarters · filed 2026-04-29 | -$3.43B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | -$780.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$1.50B derived: sum of 2 quarters · filed 2026-02-04 | -$2.63B derived: sum of 3 quarters · filed 2026-07-30 | -$3.72B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | -$717.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$1.85B derived: sum of 2 quarters · filed 2026-07-30 | -$2.94B 10-Q · filed 2025-10-28 | -$4.07B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | -$1.13B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$2.22B 10-Q · filed 2026-07-30 | -$3.35B derived: sum of 3 quarters · filed 2026-07-30 | -$3.99B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | -$1.09B 10-Q · filed 2026-04-29 | -$2.22B derived: sum of 2 quarters · filed 2026-04-29 | -$2.86B derived: sum of 3 quarters · filed 2026-04-29 | -$3.34B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | -$1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$1.77B derived: sum of 2 quarters · filed 2026-02-04 | -$2.25B derived: sum of 3 quarters · filed 2026-02-04 | -$2.20B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | -$634.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$1.11B derived: sum of 2 quarters · filed 2025-10-28 | -$1.06B 10-Q · filed 2025-10-28 | -$1.51B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | -$478.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$431.00M 10-Q · filed 2025-08-01 | -$877.10M derived: sum of 3 quarters · filed 2026-02-04 | -$1.28B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $47.10M 10-Q · filed 2025-04-29 | -$399.00M derived: sum of 2 quarters · filed 2026-02-04 | -$806.30M derived: sum of 3 quarters · filed 2026-02-04 | -$1.42B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | -$446.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | -$853.40M derived: sum of 2 quarters · filed 2026-02-04 | -$1.47B derived: sum of 3 quarters · filed 2026-02-04 | -$1.79B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | -$407.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$1.02B derived: sum of 2 quarters · filed 2024-10-31 | -$1.34B 10-Q · filed 2024-10-31 | -$1.59B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | -$614.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$936.70M 10-Q · filed 2024-08-01 | -$1.18B derived: sum of 3 quarters · filed 2025-02-05 | -$1.91B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | -$322.50M 10-Q · filed 2024-05-02 | -$570.10M derived: sum of 2 quarters · filed 2025-02-05 | -$1.30B derived: sum of 3 quarters · filed 2025-02-05 | -$1.40B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | -$247.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | -$972.60M derived: sum of 2 quarters · filed 2025-02-05 | -$1.07B derived: sum of 3 quarters · filed 2025-02-05 | -$1.01B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | -$725.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$826.10M derived: sum of 2 quarters · filed 2023-11-02 | -$761.40M 10-Q · filed 2023-11-02 | -$1.67B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | -$101.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$36.40M 10-Q · filed 2023-08-03 | -$943.00M derived: sum of 3 quarters · filed 2024-02-05 | -$557.60M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $64.70M 10-Q · filed 2023-05-04 | -$841.90M derived: sum of 2 quarters · filed 2024-02-05 | -$456.50M derived: sum of 3 quarters · filed 2024-02-05 | -$574.70M derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | -$906.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | -$521.20M derived: sum of 2 quarters · filed 2024-02-05 | -$639.40M derived: sum of 3 quarters · filed 2024-02-05 | -$1.01B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $385.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $267.20M derived: sum of 2 quarters · filed 2022-11-03 | -$99.20M 10-Q · filed 2022-11-03 | -$404.50M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | -$118.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$484.60M 10-Q · filed 2022-08-03 | -$789.90M derived: sum of 3 quarters · filed 2023-02-06 | -$177.90M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | -$366.40M 10-Q · filed 2022-05-04 | -$671.70M derived: sum of 2 quarters · filed 2023-02-06 | -$59.70M derived: sum of 3 quarters · filed 2023-02-06 | -$2.67B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | -$305.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $306.70M derived: sum of 2 quarters · filed 2023-02-06 | -$2.31B derived: sum of 3 quarters · filed 2023-02-06 | -$1.97B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $612.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$2.00B derived: sum of 2 quarters · filed 2021-11-04 | -$1.67B 10-Q · filed 2021-11-04 | -$2.01B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | -$2.61B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$2.28B 10-Q · filed 2021-08-05 | -$2.62B derived: sum of 3 quarters · filed 2022-02-07 | -$2.63B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $335.60M 10-Q · filed 2021-05-06 | -$10.10M derived: sum of 2 quarters · filed 2022-02-07 | -$21.10M derived: sum of 3 quarters · filed 2022-02-07 | -$36.40M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | -$345.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | -$356.70M derived: sum of 2 quarters · filed 2022-02-07 | -$372.00M derived: sum of 3 quarters · filed 2022-02-07 | -$252.10M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | -$11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$26.30M derived: sum of 2 quarters · filed 2020-11-05 | $93.60M 10-Q · filed 2020-11-05 | $10.60M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | -$15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $104.60M 10-Q · filed 2020-08-05 | $21.60M derived: sum of 3 quarters · filed 2021-02-08 | $25.30M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $119.90M 10-Q · filed 2020-05-05 | $36.90M derived: sum of 2 quarters · filed 2021-02-08 | $40.60M derived: sum of 3 quarters · filed 2021-02-08 | $29.40M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | -$83.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | -$79.30M derived: sum of 2 quarters · filed 2021-02-08 | -$90.50M derived: sum of 3 quarters · filed 2021-02-08 | -$77.10M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $3.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$7.50M derived: sum of 2 quarters · filed 2019-11-05 | $5.90M 10-Q · filed 2019-11-05 | $5.93M 10-Q · filed 2018-11-06 | -$204.63M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | -$11.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.20M 10-Q · filed 2019-08-06 | $2.22M 10-Q · filed 2018-08-02 | -$208.34M derived: sum of 3 quarters · filed 2020-02-07 | -$216.53M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $13.40M 10-Q · filed 2019-05-07 | $13.43M 10-Q · filed 2018-05-03 | -$197.13M derived: sum of 2 quarters · filed 2020-02-07 | -$205.33M derived: sum of 3 quarters · filed 2020-02-07 | -$71.81M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | -$210.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | -$218.73M derived: sum of 2 quarters · filed 2020-02-07 | -$85.21M derived: sum of 3 quarters · filed 2020-02-07 | -$24.40M 10-K · filed 2020-02-07 | ||||
| 2017-09-30 | -$8.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $125.32M derived: sum of 2 quarters · filed 2018-11-06 | $186.13M 10-Q · filed 2018-11-06 | -$305.65M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $133.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $194.33M 10-Q · filed 2018-08-02 | -$297.46M derived: sum of 3 quarters · filed 2019-02-07 | -$268.78M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $60.81M 10-Q · filed 2018-05-03 | -$430.98M derived: sum of 2 quarters · filed 2019-02-07 | -$402.30M derived: sum of 3 quarters · filed 2019-02-07 | -$433.50M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | -$491.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | -$463.11M derived: sum of 2 quarters · filed 2019-02-07 | -$494.31M derived: sum of 3 quarters · filed 2019-02-07 | -$700.50M 10-K · filed 2019-02-07 | -$700.39M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $28.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$2.52M derived: sum of 2 quarters · filed 2017-11-08 | -$208.71M 10-Q · filed 2017-11-08 | -$212.72M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | -$31.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$237.39M 10-Q · filed 2017-08-03 | -$241.40M derived: sum of 3 quarters · filed 2018-02-08 | -$587.04M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | -$206.19M 10-Q · filed 2017-05-04 | -$190.54M 10-Q · filed 2016-05-05 | -$210.20M derived: sum of 2 quarters · filed 2018-02-08 | -$555.85M derived: sum of 3 quarters · filed 2018-02-08 | -$559.38M derived: sum of 4 quarters · filed 2018-02-08 | |||
| 2015-12-31 | -$4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | -$349.66M derived: sum of 2 quarters · filed 2018-02-08 | -$353.19M derived: sum of 3 quarters · filed 2018-02-08 | -$262.80M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | -$345.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$349.18M derived: sum of 2 quarters · filed 2016-11-04 | -$258.79M 10-Q · filed 2016-11-04 | -$511.44M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | -$3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $86.86M 10-Q · filed 2016-08-04 | -$165.79M derived: sum of 3 quarters · filed 2017-02-09 | -$160.63M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $90.40M 10-Q · filed 2016-05-05 | $76.17M 10-Q · filed 2015-05-07 | -$162.26M derived: sum of 2 quarters · filed 2017-02-09 | -$157.09M derived: sum of 3 quarters · filed 2017-02-09 | -$237.10M derived: sum of 4 quarters · filed 2017-02-09 | |||
| 2014-12-31 | -$252.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | -$247.49M derived: sum of 2 quarters · filed 2017-02-09 | -$327.50M derived: sum of 3 quarters · filed 2017-02-09 | -$218.55M 10-K · filed 2017-02-09 | -$209.27M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$74.85M derived: sum of 2 quarters · filed 2015-11-04 | $34.11M 10-Q · filed 2015-11-04 | $43.49M 10-Q · filed 2014-11-04 | $134.72M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | -$80.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $28.94M 10-Q · filed 2015-08-04 | $37.56M 10-Q · filed 2014-08-05 | $129.56M derived: sum of 3 quarters · filed 2016-02-11 | $133.09M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | $108.95M 10-Q · filed 2015-05-07 | $209.57M derived: sum of 2 quarters · filed 2016-02-11 | $213.10M derived: sum of 3 quarters · filed 2016-02-11 | $169.62M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $100.62M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $104.15M derived: sum of 2 quarters · filed 2016-02-11 | $60.67M derived: sum of 3 quarters · filed 2016-02-11 | $72.19M 10-K · filed 2016-02-11 | $77.14M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | $3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$39.95M derived: sum of 2 quarters · filed 2014-11-04 | -$28.43M 10-Q · filed 2014-11-04 | -$101.44M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | -$43.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$31.96M 10-Q · filed 2014-08-05 | -$104.97M derived: sum of 3 quarters · filed 2015-02-12 | -$106.78M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $11.52M 10-Q · filed 2014-05-08 | -$61.49M derived: sum of 2 quarters · filed 2015-02-12 | -$63.30M derived: sum of 3 quarters · filed 2015-02-12 | -$68.37M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | -$73.01M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | -$74.82M derived: sum of 2 quarters · filed 2015-02-12 | -$79.90M derived: sum of 3 quarters · filed 2015-02-12 | -$97.65M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$6.89M derived: sum of 2 quarters · filed 2013-11-05 | -$24.64M 10-Q · filed 2013-11-05 | $336.80M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | -$5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | -$22.83M 10-Q · filed 2013-08-06 | $338.61M derived: sum of 3 quarters · filed 2014-02-13 | $338.33M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | -$17.75M 10-Q · filed 2013-05-03 | $343.69M derived: sum of 2 quarters · filed 2014-02-13 | $343.41M derived: sum of 3 quarters · filed 2014-02-13 | $353.46M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $361.44M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $361.16M derived: sum of 2 quarters · filed 2014-02-13 | $371.21M derived: sum of 3 quarters · filed 2014-02-13 | $384.25M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | -$279.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $9.77M derived: sum of 2 quarters · filed 2012-10-24 | $22.81M 10-Q · filed 2012-10-24 | $205.57M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $10.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $23.09M 10-Q · filed 2012-07-25 | $205.85M derived: sum of 3 quarters · filed 2013-02-15 | $207.46M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $13.04M 10-Q · filed 2012-04-26 | $195.80M derived: sum of 2 quarters · filed 2013-02-15 | $197.41M derived: sum of 3 quarters · filed 2013-02-15 | $200.13M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $182.76M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $184.37M derived: sum of 2 quarters · filed 2013-02-15 | $187.09M derived: sum of 3 quarters · filed 2013-02-15 | $243.31M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $1.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $4.33M derived: sum of 2 quarters · filed 2011-10-27 | $60.55M 10-Q · filed 2011-10-27 | $82.88M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $58.93M 10-Q · filed 2011-07-28 | $81.26M derived: sum of 3 quarters · filed 2012-02-21 | $83.41M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $56.22M 10-Q · filed 2011-05-03 | $78.54M derived: sum of 2 quarters · filed 2012-02-21 | $80.69M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | $22.33M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $24.48M derived: sum of 2 quarters · filed 2012-02-21 | $31.36M 10-K · filed 2012-02-21 | |||||
| 2009-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $9.04M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $6.89M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | -$192.86M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |